close
Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

Open innovation networks between academia and industry: an imperative for breakthrough therapies

Nature Medicine volume 15, pages 502–507 (2009) Cite this article

Save article
View saved research

The demand to bring transformative therapeutics to patients and the escalating costs of doing so are driving the life science industry to seek collaborations with academia to stimulate innovation. Despite the opportunities afforded by working together, companies and universities lack a systematic approach for capturing the full potential of such relationships. Detailed here are a few suggested strategies to help these collaborations succeed.

Since the beginning of 2008 alone, Merck, GlaxoSmithKline, AstraZeneca and Pfizer have all established multimillion-dollar, multiyear collaborations with academic institutes across a number of therapeutic areas4,5. Although some of these relationships are built on long-standing collaborations with academic institutions, the recent increase in the number of these collaborative relationships is part of a major change in strategic direction. These partnerships come at a crucial time for both industry and universities and have the potential to profoundly alter the means by which healthcare is delivered. An important aim for both types of organizations is to close the gap between basic and clinical research, thereby allowing for a more evidence- and outcomes-based approach to therapeutic development that provides real healthcare value to patients. This requires the development of new testing technologies to clearly identify who will benefit most from each therapeutic treatment and determine the conditions under which the benefit will be achieved6,7. Despite the commitment of organizations to foster healthcare innovation along these lines, most companies and universities still lack a systematic and coordinated approach to entering into these relationships or capturing the most value from them.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The current model for producing biopharmaceutical innovation is economically unsustainable.
BERJAYA
Figure 2: How to manage industry-academic partnerships as one would an investment portfolio.
BERJAYA

References

  1. Chesbrough, H.W. Open Innovation: The New Imperative for Creating And Profiting from Technology (Harvard Business School Press, Boston, 2003)

    Google Scholar 

  2. Chesbrough, H.W. Open Business Models: How to Thrive in the New Innovation Landscape (Harvard Business School Press, Boston, 2006)

    Google Scholar 

  3. Jones, A. & Clifford, L. Nat. Rev. Drug Discov. 4, 807–808 (2005).

    Article  CAS  Google Scholar 

  4. Hughes, B. Nat. Rev. Drug Discov. 7, 631–632 (2008).

    Article  CAS  Google Scholar 

  5. Jarvis, L.M. Chem. Eng. News 86, 13–20 (2008).

    Google Scholar 

  6. Phillips, K.A. J. Am. Med. Assoc. 300, 2542–2544 (2008).

    Article  CAS  Google Scholar 

  7. Deverka, P.A., Doksum, T. & Carlson, R.J. Clin. Pharmacol. Ther. 82, 427–434 (2007).

    Article  CAS  Google Scholar 

  8. Wilan, K.H. Cell 129, 847–850 (2007).

    Article  CAS  Google Scholar 

  9. Stossel, T.P. N. Engl. J. Med. 353, 1060–1065 (2005).

    Article  CAS  Google Scholar 

  10. White, A.P. et al. Spine 32, S53–S57 (2007)

    Article  Google Scholar 

  11. Korn, D. J. Am. Med. Assoc. 284, 2234–2237 (2000).

    Article  CAS  Google Scholar 

  12. Brennan, T.A. et al. J. Am. Med. Assoc. 295, 429–433 (2006).

    Article  CAS  Google Scholar 

  13. Gordon, M. & Ertel, D. Point of the Deal: How to Negotiate When Yes Is Not Enough (Harvard Business School Press, Boston, 2007)

    Google Scholar 

  14. Melese, T. Res. Manage. Rev. 15, 13–21 (2006).

    Google Scholar 

  15. Zerhouni, E.A. N. Engl. J. Med. 353, 1621–1623 (2005).

    Article  CAS  Google Scholar 

  16. Carpenter, S. Science 317, 966–967 (2007).

    Article  Google Scholar 

  17. Bernstein, K. BioCentury 14, A1–A5 (2006).

    Google Scholar 

  18. Heller, M.A. & Eisenberg, R.S. Science 280, 698–701 (1998).

    Article  CAS  Google Scholar 

  19. Chesbrough, H.W. & Appleyard, M.M. Calif. Manage. Rev. 50, 57–76 (2007).

    Article  Google Scholar 

  20. Travis, J. Science 319, 1750–1752 (2008).

    Article  CAS  Google Scholar 

  21. Nathan, C. Nat. Med. 13, 304–308 (2007).

    Article  CAS  Google Scholar 

  22. Verrils, N.M. Clin. Biochem. Rev. 27, 99–116 (2006).

    Google Scholar 

  23. Blow, N. Nat. Meth. 5, 361–368 (2008).

    Article  CAS  Google Scholar 

  24. Altar, C.A. Clin. Pharmacol. Ther. 83, 361–364 (2008).

    CAS  Google Scholar 

  25. Saxena, R. Science 316, 1331–1336 (2007).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors thank E. Lium and T. Shen for contributing to the article.

Author information

Authors and Affiliations

  1. Teri Melese is in the Department of Medicine at the University of California–San Francisco, San Francisco, California, USA.,

    Teri Melese

  2. Salima M. Lin and Julia L. Chang are at IBM Global Business Services, Armonk, New York, USA.,

    Salima M Lin & Julia L Chang

  3. Neal H. Cohen is in the Departments of Anesthesia and Perioperative Care and Medicine, University of California–San Francisco, San Francisco, California, USA.,

    Neal H Cohen

Authors
  1. Teri Melese
    View author publications

    Search author on:PubMed Google Scholar

  2. Salima M Lin
    View author publications

    Search author on:PubMed Google Scholar

  3. Julia L Chang
    View author publications

    Search author on:PubMed Google Scholar

  4. Neal H Cohen
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Teri Melese.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Melese, T., Lin, S., Chang, J. et al. Open innovation networks between academia and industry: an imperative for breakthrough therapies. Nat Med 15, 502–507 (2009). https://doi.org/10.1038/nm0509-502

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/nm0509-502

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing